Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease T. A. CARACENI, I. CELANO, E. PARATI, AND F. GIROTTI From the Istituto Neurologico 'C. Besta', Milan, Italy S U M M A R Y Twenty-six patients affected by Parkinson's disease were treated with a 2-Br-alphaergocriptine (CB 154): 14 cases were given CB 154 alone, and 12 were given CB 154 along with L-dopa plus benserazide (Madopar) . Both CB 154 and combined therapy (CB 154+Madopar) induced a significant improvement in total disability score, tremor, rigidity, akinesia, selfsufficiency, and some motor performance tests (dynamic tests 2-bromo-a-ergocriptine (CB 154) is an ergot alkaloid which has been proved effective in suppressing lactation and inhibiting prolactin secretion (Fluckiger and Wagner, 1968; Billiter and Fluckiger, 1971) . As several experimental studies on animals (Corrodi et al., 1973; Miyamoto et al., 1974; Goldstein et al., 1975) showed that CB 154 has a dopamine stimulating effect both at presynaptic and postsynaptic levels, bromocriptine has been used in the treatment of Parkinson's disease (Calne et al., 1974; Lieberman et al., 1976a; Gerlach, 1976; Parkes et al., 1976; Gautier and Durand, 1977) .
Another ergoline derivate (lergotrile), which reduces plasma prolactin concentration has been tried in the treatment of Parkinson's disease with not very satisfactory results (Lieberman et al., 1975) . The results obtained with CB 154 in the treatment of Parkinson's disease are certainly valid although with different effects observed by different authors. According to Kartzinel et al. (1976a) CB 154 is more effective than L-dopa plus carbidopa (Sinemet), while Gerlach (1976) notes that CB 154 is less effective than L-dopa plus benserazide (Madopar). Lieberman et al. (1976b) claim that CB 154 would be useful in patients no longer responding to L-dopa. The addition of caffeine did not enhance the antiparkinsonism potency of ergocriptine (Kartzinel et al., 1976b) .
Taking this diversity of opinions regarding the therapeutic effectiveness of 2-bromo-a-ergocriptine into account, it seemed interesting to compare the results obtained with the various therapies as follows: (1) These tests were given to the patients once a week for the entire period of the pharmacological trials, and the scores were derived from the mean observation of three different examiners. The best scores of the various tests were used for the statistical evaluation. Statistical analysis was performed using a paired t test (Student's t test).
Careful attention was directed to possible changes of pulse rate, respiration, and standing and lying blood pressure. Side effects such as constipation, nausea, vomiting, asthenia, mouth dryness, psychic disturbance, dyskinesia, paradoxical akinesia, and on-off phenomenon were taken into consideration. Haematological, hepatic, and renal function tests were done before, during, and after our investigation. T. The side effects are shown in Table 3 . Gastric disturbances (pain, nausea, vomiting) were most frequent but could be relieved with a simple 
Discussion
These results clearly show the effectiveness of bromocriptine (CB 154) in the treatment of Parkinson's disease and are comparable with those previously reported by Kartzinel et al. (1976c) and Parkes et al. (1976) . Rigidity and akinesia were significantly reduced, whereas tremor was less effectively alleviated. The appearance of tremor was slight in our patients, and we, therefore, suggest that the statistical analysis might change in a larger population. The scores of self-sufficiency and dynamic tests were also significantly improved ( Table 2 ). The effectiveness of combined therapy (CB 154 plus Madopar) was significantly higher than that of Madopar alone. There was no significant difference between CB 154 and Madopar treatment although the former therapy seems to be more efficient than the latter (Table 2 and Fig. 1) .
A placebo effect must be considered, but we do not attribute the improvement obtained to this in view of the long duration of effectiveness of the treatment, the nature of the disease, its organic basis, and the objective evaluation of clinical signs.
The necessity for rather high doses of CB 154 (mean 60 mg/day) has been demonstrated. The mean dose is a little lower than that of Kartzinel et al. (1976a) who, in some arbitrary way, proposed the maximum level of 100 mg/day. These data are at variance with those of Gerlach (1976) who, using smaller dosages, did not find the same improvement in his patients; otherwise our data agree with those of Kartzinel et al. (1976a) who compared the results obtained by CB 154 treatment with those obtained by treatment with Ldopa plus carbidopa (Sinemet).
Taking into consideration the dosage, the effectiveness of CB 154 is maximal at the lower doses (30 mg a day), while continuing improvement seen at the higher doses (60-80 mg/day) is less marked (Fig. 2) , confirming the previous observations of Kartzinel et al. (1976a) .
The addition of CB 154 to Madopar treatment permitted us to reduce the previous treatment by about 50% in quantity and the number of daily doses.
The side effects of CB 154 are similar to those appearing with L-dopa treatment whether or not associated with a decarboxylase inhibitor. We underline the unusual appearance of a depressive reaction in five patients. Two of the latter had an identical reaction with Madopar treatment, suggesting unpredictable hypersensitivity to dopaminergic stimuli in these cases.
On-off phenomenon or important swings in symptomatology during CB 154 therapy were never observed, and were seen in only one case during CB 154 plus Madopar treatment. This observation, even if restricted to a limited number of patients, seems to confirm the usefulness of bromocriptine in reducing the on-off phenomenon as suggested by Kartzinel and Calne (1976) .
In conclusion, on the basis of the results of these trials, we sugggest that CB 154 alone and combined therapy with CB 154 and Madopar, even if further investigations are required, is an important advance in the management of Parkinson's disease.
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